Central Alerting System
View Alert
Versions:


Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: Originally issued on 25-Feb-2020 14:03:40. This version was issued on 25-Feb-2020 14:03:40

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Social Care Providers (registered with CAS)
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Primary Care Networks

Action category: Action

Title: Epanutin (phenytoin) 30mg/5ml Oral Suspension - Supply Disruption Alert

Broadcast content:
Epanutin® (phenytoin) 30mg/5ml oral suspension will be out of stock from w/c 2nd March until late June 2020.

The Canadian brand of phenytoin 30mg/5ml oral suspension - ‘Dilantin-30®’ - is equivalent to Epanutin® 30mg/5ml oral suspension and supplies are available to order on an ‘unlicensed’ basis as via the Pfizer customer contact centre on 0845 608 8866. The product comes as a 250ml presentation.

Different formulations of phenytoin (other than Dilantin® 30mg/5ml oral suspension) are not interchangeable and if patients are switched to anything other than ‘Dilantin® (phenytoin) 30mg/5mL oral suspension’ careful management of switching and monitoring is required which may require specialist advice, support, or referral.

The Canadian brand of phenytoin 30mg/5ml oral suspension - ‘Dilantin-30®’ - is equivalent to Epanutin® 30mg/5ml oral suspension and supplies are available on an ‘unlicensed’ basis.

This alert contains advice on the management of affected patients and includes three download documents of supporting information.



Additional information: NHS Regional Offices: please cascade this alert to community pharmacy and to GP Practices not yet registered with CAS.

Alert reference: SDA/2020/002

Action underway deadline: 27-Feb-2020

Action complete deadline: 19-Jun-2020

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency